AstraZeneca plc (AZN) Stock Rating Reaffirmed by Societe Generale

AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating restated by stock analysts at Societe Generale in a research report issued to clients and investors on Thursday.

Other equities research analysts have also recently issued reports about the stock. Liberum Capital reissued a “buy” rating and issued a GBX 5,500 ($74.15) target price on shares of AstraZeneca plc in a research report on Monday, June 5th. Deutsche Bank AG reissued a “buy” rating and issued a GBX 5,700 ($76.85) target price on shares of AstraZeneca plc in a research report on Monday, June 5th. Kepler Capital Markets reissued a “buy” rating and issued a GBX 5,500 ($74.15) target price on shares of AstraZeneca plc in a research report on Monday, June 5th. Morgan Stanley reissued a “buy” rating on shares of AstraZeneca plc in a research report on Tuesday, June 6th. Finally, Citigroup Inc. reissued a “buy” rating on shares of AstraZeneca plc in a research report on Wednesday, July 5th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company’s stock. AstraZeneca plc presently has a consensus rating of “Hold” and a consensus price target of GBX 5,041.09 ($67.97).

ILLEGAL ACTIVITY WARNING: “AstraZeneca plc (AZN) Stock Rating Reaffirmed by Societe Generale” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://ledgergazette.com/2017/09/21/astrazeneca-plc-azn-rating-reiterated-by-societe-generale.html.

In other AstraZeneca plc news, insider Nazneen Rahman bought 39 shares of the stock in a transaction on Thursday, July 27th. The stock was purchased at an average price of GBX 4,370 ($58.92) per share, for a total transaction of £1,704.30 ($2,297.83).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply